Activity of Thalidomide in Waldenström’s Macroglobulinemia

Publication
Article
OncologyONCOLOGY Vol 14 No 11
Volume 14
Issue 11

Thalidomide (Thalomid) is a potent teratogen and sedative that inhibits angiogenesis. Based on the activity of this agent in patients with multiple myeloma, we initiated a phase II study in Waldenstrom’s macroglobulinemia.

Thalidomide (Thalomid) is a potent teratogen and sedative that inhibits angiogenesis. Based on the activity of this agent in patients with multiple myeloma, we initiated a phase II study in Waldenstrom’s macroglobulinemia.

Oral thalidomide was administered on a dose-escalating schedule of 200 mg daily ´ 14 days, with a dose escalation of 200 mg every 2 weeks to a maximum dose of 600 mg. Between July and November 1999, eight patients were included. The median age was 72 years (range: 63–84 years), hemoglobin was < 10.0 g/dL in four patients, serum monoclonal IgM was > 3.0 g/dL in seven patients, and lymphadenopathy or splenomegaly was present in six patients. Three patients were previously untreated, three were primary refractory and two were treated during refractory relapse.

Among the seven patients evaluable for response so far, three have achieved at least a 50% reduction of serum monoclonal protein, in one patient the serum monoclonal protein was stable, and in three patients there was disease progression. At least a 25% protein reduction was noted in the three eventual responders within 4 weeks of thalidomide therapy. A significant reduction of organomegaly and splenomegaly occurred in responding patients. Toxicities included transient somnolence in all patients, moderate fatigue in three patients, and severe constipation in four patients; mild myelosuppression and tremor were noted in one patient each.

CONCLUSION: While patient accrual is ongoing, it appears that thalidomide has a biologic effect in Waldenstrom’s macroglobulinemia.

Click here to read James R. Berenson's commentary on this abstract.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Related Content